What is Thrombolytic Science?
Thrombolytic Science, LLC operates as a specialized, clinical-stage biotechnology enterprise dedicated to transforming the standard of care for thrombotic diseases. The company is primarily focused on addressing acute vascular conditions, including ischemic stroke and myocardial infarction, through the development of a proprietary dual thrombolytic regimen. By prioritizing the delivery of intravenous biotherapy closer to the onset of symptoms, the organization aims to significantly improve patient outcomes and expand access to life-saving medical interventions. Their current clinical trials represent a pivotal effort to validate a novel approach to restoring blood flow, positioning the company as a key innovator in the cardiovascular therapeutic market.
How much funding has Thrombolytic Science raised?
Thrombolytic Science has raised a total of $7.5M across 1 funding round:
Unspecified
$7.5M
Unspecified (2012): $7.5M, investors not publicly disclosed
Key Investors in Thrombolytic Science
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Thrombolytic Science?
Looking ahead, the strategic deployment of this capital will likely focus on the progression of clinical trials and the refinement of their dual thrombolytic regimen. As the company moves deeper into its clinical development phase, the focus will shift toward demonstrating safety and efficacy profiles that meet rigorous regulatory standards. This funding provides the necessary runway to scale operations and potentially establish partnerships with healthcare providers, ensuring that their advanced treatment options can be integrated into acute care settings. The company remains committed to its mission of reducing the morbidity associated with vascular blockages, with future milestones likely centered on data readouts and potential commercialization pathways.
See full Thrombolytic Science company page
